IGI Laboratories, Inc. Completes Filing of Two Product Development ANDAs Wiith the FDA

Published: Jan 04, 2013

BUENA, N.J.--(BUSINESS WIRE)--IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it filed two abbreviated new drug applications, or ANDAs, on December 28 and December 31, 2012 in accordance with one of its customer development agreements. The company executed the customer development agreement earlier in 2012, and completed the development of the two topical generic drug products and filing of the related ANDAs by year end. Upon FDA approval, the company will manufacture and package the products in the customer’s label.

Back to news